Drug Profile
Research programme: opioid agonists - BTG
Alternative Names: BTG-6001Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator CLL PHARMA
- Developer BTG
- Class
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postoperative pain
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 01 Jan 2013 Discontinued - Preclinical for Postoperative pain in United Kingdom (PO)
- 12 Feb 2009 Preclinical development is ongoing in United Kingdom